Lendin Neo

Bilastine, the active ingredient in Lendin Neo, is a second‑generation H1 antihistamine presented as an oral tablet for oral use. It treats allergic rhinitis and chronic idiopathic urticaria in adults and adolescents.

GNH USA supplies Lendin Neo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bilastine is a second‑generation H1 antihistamine used to manage allergic conditions by blocking peripheral H1 receptors.

- Allergic rhinitis: Reduces nasal congestion, itching, sneezing and rhinorrhea associated with seasonal or perennial allergens. - Chronic idiopathic urticaria: Decreases the frequency and severity of hives and associated itching in patients with persistent spontaneous urticaria.

Bilastine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported during early treatment. - Dry mouth: sensation of oral dryness without overt salivation loss. - Fatigue: transient tiredness that usually resolves with continued use. - Nausea: occasional upset stomach or queasiness. - Somnolence: low‑grade sleepiness, less frequent than first‑generation antihistamines. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome: rare skin eruption with blistering and mucosal involvement. - Cardiac arrhythmia: extremely uncommon disturbances in heart rhythm. - Hepatic injury: rare liver enzyme elevations. - Severe hypersensitivity: rash, swelling, or difficulty breathing. - Thrombocytopenia: low platelet count observed in isolated cases.

Bilastine should be used according to professional guidance and with awareness of specific safety considerations.

- Hypersensitivity: Discontinue if any signs of allergic reaction such as rash, itching, or swelling appear. - Renal or hepatic impairment: Use with caution; dose adjustment may be required based on clinical judgment. - Concomitant CNS depressants: Avoid or monitor when combined with alcohol or sedative medications. - Pediatric use: Not recommended for children under 12 years unless specifically prescribed. - Pregnancy and lactation: Safety has not been established; discuss risks with a healthcare provider. - Store below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Bilastine may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Ketoconazole: Strong CYP3A4 inhibition can raise bilastine plasma levels. - Erythromycin: Inhibits intestinal transporters, increasing exposure. - Diltiazem: May elevate bilastine concentrations, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: Can reduce bilastine absorption; separate dosing by at least 2 hours. - Fruit juices (e.g., grapefruit, orange): May decrease oral bioavailability; advise taking with water. - Other antihistamines: Additive sedation or reduced efficacy; monitor patient response.